Navigating New Data in the Breast Cancer Treatment Paradigm | Supplements and Featured Publications

November 07, 2024

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

November 06, 2024

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

November 05, 2024

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

September 15, 2024

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

September 14, 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

September 13, 2024

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

June 20, 2024

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

June 19, 2024

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

June 13, 2024

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

June 07, 2024

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

June 07, 2024

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.